EFC1580 BOREAS: A randomized double blind placebo controlled parallel group 52wk study to assess the efficacy, safety, and tolerability of Dupilumab in patients with moderate to severe COPD w/Type 2

Administered By

Contributors

Start/End

  • June 19, 2019 - June 30, 2021